License and Collaboration Agreements, BioSense License and Assignment Agreement (Details)		12 Months Ended
	Mar. 10, 2020 USD ($)	Dec. 31, 2023 USD ($) Milestone Country	Dec. 31, 2021 USD ($)
BioSense License and Assignments Agreement [Member]
Collaboration and License Agreement [Abstract]
Non-refundable cash payment received	$ 1,650,000
Milestone payment achieved for performance obligation, recorded as collaboration revenue			$ 100,000
Milestone payments received		$ 0
Maximum amount of payments receivable for development, regulatory and commercial milestones		84,500,000
BioSense License and Assignments Agreement [Member] | Rexahn [Member]
Collaboration and License Agreement [Abstract]
Non-refundable cash payment received	$ 1,550,000
Processa License Agreement [Member]
Collaboration and License Agreement [Abstract]
Milestone payments received		$ 0
Number of times sales milestone payments | Milestone		1
Percentage of milestone payments eligible to receive on sub-license agreement		32.00%
Number of countries | Country		1
Milestone period to administer drug clinical trial of licensed product on first patient		3 years
Milestone period to administer drug clinical trial of licensed product on first patient for second indication		5 years
Period of opportunity to cure breach of agreement		120 days
Period of prior written notice to be served for termination of agreements		120 days